Sample Program
We are pleased to provide the Alpha-1 community with the option of trying
Zemaira® at no charge for up to 2 weeks. To obtain a Trial
Pack of Zemaira® for one of your patients, simply complete
the Zemaira® Product
Sample Request form 
and fax it to our Customer Support group at the
number shown on the form. Please note that Zemaira® samples
can be requested only on a per-patient basis.
Should you decide to continue your patient on Zemaira®, one of our Specialty Pharmacy Partners, Accredo Therapeutics and Coram, Inc., (a division of Aprial Healthcare) can provide you with assistance. You will need to obtain the necessary insurance clearance and set up an infusion service. Because it can take up to 4 weeks to complete this process, we encourage you to work with your patient to fill out the referral form and fax it to the selected specialty pharmacy at the same time you fax us the Product Sample Request. That way, all the paperwork necessary for your patient to continue on Zemaira® should be completed by the end of the trial period.
Accredo Referral Form for Zemaira®
Coram, Inc. Referral Form for Zemaira®
For more information about the Zemaira® Sample Program, please call
1-866-ZEMAIRA (1-866-936-2472).
Important Safety Information
Alpha1-Proteinase Inhibitor (Human), Zemaira® is indicated for chronic augmentation and maintenance therapy for adults with alpha1-proteinase inhibitor (A1-PI) deficiency and emphysema. Clinical data demonstrating the long-term effects of chronic augmentation therapy with Zemaira® are not available.
Zemaira® may not be appropriate for the following adult individuals as they may experience severe reactions, including anaphylaxis: individuals with a known hypersensitivity and/or history of anaphylaxis or severe systemic reaction to A1-PI products or their components, and individuals with selective IgA deficiencies who have known antibodies against IgA.
In clinical studies, the following treatment-related adverse reactions were reported in 1% of subjects: asthenia (fatigue), injection-site pain, dizziness, headache, paresthesia (tingling), and pruritus (itching).
Zemaira® is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.
Please see full prescribing information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
The information provided herein is solely for use by physicians and healthcare professionals in the United States. The CSL Behring product listed may not have been approved in other countries and may not be available everywhere.